Jedd Wolchok

Jedd Wolchok is one of the pioneers of cancer checkpoint immunotherapy and a global authority on melanoma treatment. He led landmark clinical trials establishing the efficacy of ipilimumab plus nivolumab combination immunotherapy, producing unprecedented 5-year survival rates in metastatic melanoma. His laboratory investigates mechanisms of response and resistance to checkpoint blockade and is developing next-generation immunotherapy combinations. His work has transformed the treatment of melanoma and served as a template for immunotherapy across tumor types.